Oncology · Medical Literature
[Correspondence] Risks of modelling cancer outcomes when no data exist – Authors' reply
Abstract
We thank Atif Kamal for his engagement and agree that investment in population-based cancer registries is important, especially when data are scarce.
Clinical relevance
Do simulation-based microsimulation models that estimate global cancer outcomes in settings with absent or sparse population-based registry data introduce unacceptable epistemic risks, and how should such risks be understood, communicated, and mitigated? __SNAPSHOT__ {"studyDesign":"Correspondence (Authors' reply to a published letter); no original empirical data generated","setting":"Not applicable (journal correspondence in response to a critique of previously published simulation-based analyses in The Lancet Oncology, 2026)","sampleSize":"Not applicable","population":"Not applicable; the intellectual subject concerns modelled populations across 200 countries and territories for 17 cancer types, as described in the companion Ward et al. simulation articles (Lancet Oncol 2026;27:551–579)","intervention":"Authors' methodological defence and clarification of the Global Cancer Workforce microsimulation model used to estimate cancer incidence, stage, survival, mortality, and workforce needs in data-scarce settings","comparator":"Not applicable","primaryOutcome":"Not applicable; the correspondence addresses epistemological and methodological concerns about the validity and appropriate use of simulation modelling when empirical cancer registry data are absent or incomplete","followUp":"Not applicable","fundingSource":"Not reported in the abstract"}
Key findings
This is a brief authors' reply correspondence containing no original quantitative findings, effect sizes, confidence intervals, or p-values. The abstract consists of a single substantive sentence in which the authors acknowledge agreement with the correspondent (Atif Kamal) that investment in population-based cancer registries is important, particularly in data-scarce settings. No numerical data, model outputs, or statistical comparisons are reported or refuted in the available abstract text. The authors' position — as inferable from the abstract alone — is one of partial concurrence with the critique while presumably defending the methodological validity and policy utility of simulation modelling when registry data are unavailable. No additional claims can be extracted from the abstract without speculation.
Practice implications
This correspondence does not establish, refute, or modify any clinical or epidemiological finding. Its relevance is methodological and epistemological: it engages with the foundational question of whether simulation models should be used to estimate cancer burden in countries or regions where ground-truth registry data are absent. The companion Ward et al. simulation series (Lancet Oncol 2026;27:551–579) estimated cancer incidence, stage distribution, survival, mortality, and workforce needs across 200 countries using the Global Cancer Workforce microsimulation model — a model that, by design, must rely on indirect calibration, expert opinion, and data extrapolation in low-data settings. The correspondence implicitly acknowledges a core tension in global health modelling: the risk of false precision in estimates derived from sparse or absent empirical data versus the public health imperative to characterise the cancer burden in precisely those regions most underserved by cancer registries. Clinicians and health system planners should interpret simulation-derived estimates for data-scarce regions with explicit awareness of model uncertainty and should not treat such estimates as equivalent in reliability to registry-based data. The extent of the authors' methodological defence and any specific responses to Kamal's critique cannot be assessed, as only the abstract is available. __LIMITATIONS__ 1. Only the abstract is available; the full text of the correspondence is inaccessible, preventing complete assessment of the authors' arguments or the specific methodological concerns raised by Kamal. 2. As a correspondence piece (authors' reply), this document does not undergo the same peer-review scrutiny as original research. 3. The abstract contains only one substantive sentence of content, making any detailed methodological appraisal impossible without the full text. 4. The underlying simulation models to which this correspondence refers are themselves subject to substantial methodological limitations inherent to microsimulation in data-scarce settings: reliance on surrogate or extrapolated inputs, unverifiable parameter assumptions, model dependency on expert opinion surveys, limited external validation in LMICs, and the risk that uncertainty intervals underestimate true epistemic uncertainty. 5. The specific nature and scope of Kamal's critique are unknown from the abstract alone, precluding assessment of whether the authors' reply is complete or sufficient. 6. No conflict of interest declarations are reported in the abstract. __BOTTOM_LINE_CATEGORY__ low_certainty __BOTTOM_LINE__ This authors' reply correspondence acknowledges agreement with the critique that investment in population-based cancer registries is essential, particularly where data are scarce — a concession that itself underscores a fundamental limitation of the accompanying simulation modelling series. Clinicians and health policy stakeholders should treat simulation-derived cancer burden estimates for data-scarce regions as hypothesis-generating and planning tools rather than definitive epidemiological measures, and should advocate for expanded cancer registry infrastructure as the only durable solution to the data gap these models attempt to bridge. The full text is required for a complete methodological appraisal.